Evommune Inc
Veridion Score
Composite trend over time
Why is EVMN moving today?
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.
Real vendor fields plus Veridion-computed history. Missing fields stay blank.
Warehouse intelligence for EVMN.
EVMN insider activity
Evommune Inc
3 insiders bought in the last 90 days
Net buying: $18.3M across loaded Form 4 rows.
Loaded official disclosures do not show all three sources aligned on this ticker.
| Filing date | Trade date | Insider | Title | Type | Price | Qty | Owned | Value | Receipt |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-03 | 2026-06-02 | Cohen David E | Insider | sell | $21.38 | 600 | 17,609 | $13K | SEC Form 4 |
| 2026-06-03 | 2026-06-02 | Cohen David E | Insider | sell | $20.21 | 5,456 | 18,209 | $110K | SEC Form 4 |
| 2026-06-03 | 2026-06-01 | Patel Jeegar Pravinkumar | Insider | sell | $22.74 | 16,687 | 46,403 | $379K | SEC Form 4 |
| 2026-06-03 | 2026-06-01 | Patel Jeegar Pravinkumar | Insider | buy | $3.84 | 13,512 | 63,090 | $52K | SEC Form 4 |
| 2026-06-03 | 2026-06-01 | Pena Luis C. | Insider | sell | $22.74 | 16,787 | 637,896 | $382K | SEC Form 4 |
Showing 5 recent rows. Sovereign unlocks 14 additional rows, full sorting, and the named-filer history.
Upgrade to Sovereign · $25/moEVMN contract awards, year to date.
Public federal awards linked to this ticker.
EVMN lobbying filings, year to date.
Registered lobbying filings matched to Evommune Inc.